Abstract:Ethnopharmacological relevance: The root of Scutellaria baicalensis Georgi has been used extensively in traditional Chinese medicine for the treatment of inflammation, fever, cough, dysentery, and hypertension. Baicalein is a flavonoid isolated from the root of Scutellaria baicalensis Georgi and is a novel neuroprotective agent under development for the treatment of Parkinson's disease. We aimed to investigate the pharmacokinetic (PK) properties of baicalein and its main metabolite, bacalin, after single-dose administration in healthy Chinese subjects. The safety and tolerability of baicalein were also assessed.Materials and methods: This was a Phase I, randomized, double-blind, single-dose trial of baicalein (1002800 mg) in 72 healthy adults. Samples of blood, urine and feces were collected at regular intervals up to 48 h after administration of the study drug. Baicalein and baicalin were then analyzed using liquid chromatography-tandem mass spectrometry (LC/MS/MS). The maximum concentration that the drug achieved after dosing (C-max), time to C-max (T-max), terminal half-life (t(1/2)), area under the curve from time zero to time of last quantifiable concentration (AUC((0,t))), area under the curve from time zero to infinity (AUC(0,,x,)), apparent total plasma clearance (CL/F), and apparent total volume of distribution (V/F) were determined using non-compartmental models. Dose proportion was tested using a method combining the equivalence criterion and power model. Physical examinations, vital signs, ECG findings, hematology, and urinalysis were monitored before and at regular intervals after administration of the study drug. Results: The PK profile of baicelein and baicelin was characterized by a median Tmax of 0.75-3.5 h and 0.5-3 h, respectively, followed by a multiphasic profile with a t(1/2) of 1.90-15.01 h and 4.22-10.80 h, respectively. The estimates of the proportionality coefficient (90% CI) for Cm, ADC, and AUC0_, 0 were 0.83 (0.70-0.96), 0.91 (0.81-1.00) and 0.92 (0.82-1.02), respectively. All values overlapped within the pre-specified range of (0.89-1.11), (0.93-1.07), and (0.93-1.07), respectively. Dose proportionality was inconclusive for a baicalein dose range of 100-2800 mg. The total urinary clearance of baicalein and baicalin was < 1%. Approximately 27% of baicalein was eliminated as unchanged drug in feces. Baicalein was well tolerated. Eleven treatment-related adverse events were observed, and all were rated as "mild" and resolved without further treatment. No serious adverse events occurred.Conclusions: Single oral doses of 100-2800 mg of baicalein were safe and well tolerated by healthy subjects. Clinical laboratory assessments showed no signs of toxicity in the liver or kidney. The favorable safety profile and PK properties warrant further clinical studies for baicalein. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers

Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of Baicalein Chewable Tablets in Healthy Subjects.

Safety, Tolerability, and Pharmacokinetics of Oral Baicalein Tablets in Healthy Chinese Subjects: A Single‐center, Randomized, Double‐blind, Placebo‐controlled Multiple‐ascending‐dose Study

Safety, Tolerability, Pharmacokinetics, and Food Effect of Baicalein Tablets in Healthy Chinese Subjects: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Phase I Study.

In Vitro and in Situ Evaluation of Herb–drug Interactions During Intestinal Metabolism and Absorption of Baicalein

Baicalein Protects Against 6-Ohda-Induced Neurotoxicity Through Activation Of Keap1/Nrf2/Ho-1 And Involving Pkc Alpha And Pi3k/Akt Signaling Pathways

Simultaneous Determination Of Baicalein And Baicalin In Human Plasma By High Performance Liquid Chromatograph-Tandem Spectrometry And Its Application In A Food-Effect Pharmacokinetic Study

Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons

Progress in Pharmacokinetic Researches of Baicalein

Comparative pharmacokinetics of baicalin after oral administration of pure baicalin, Radix scutellariae extract and Huang-Lian-Jie-Du-Tang to rats.

Pharmacokinetics and Safety Evaluation in Healthy Chinese Volunteers of Alkaloids from Leaf of Alstonia Scholaris: A Multiple Doses Phase I Clinical Trial.

Baicalein attenuates the neuroinflammation in LPS-activated BV-2 microglial cells through suppression of pro-inflammatory cytokines, COX2/NF-κB expressions and regulation of metabolic abnormality

Pharmacokinetics and Brain Distribution Differences of Baicalin in Rat Underlying the Effect of Panax Notoginsenosides after Intravenous Administration

Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal.

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Bioequivalence Study of Baicalin Tablets in Healthy Volunteers by HPLC-MS/MS

Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats.

Pharmacokinetics, Safety, and Tolerability of Amygdalin and Paeoniflorin after Single and Multiple Intravenous Infusions of Huoxue-Tongluo Lyophilized Powder for Injection in Healthy Chinese Volunteers.

Safety, tolerance, and pharmacokinetics of salvianolic acid B in healthy Chinese volunteers: A randomized, double-blind, placebo-controlled phase 1 clinical trial

Population pharmacokinetic analysis of baicalin after oral administration of different Shuang-Huang-Lian formulations to rats

Preparation of baicalein solid dispersions and oral bioavailability in rats